Analysts are tipping three S&P/ASX 200 Index (ASX: XJO) shares to lift to a higher value than their current share prices.
Resmed Inc (ASX: RMD), Vicinity Centres (ASX: VCX), and Scentre Group (ASX: SCG) shares have all just been upgraded by brokers.
Let’s take a look at these three ASX 200 shares in more detail.
Resmed
This ASX 200 healthcare share develops and supplies medical devices to treat sleep and respiratory conditions. The company’s revenue lifted 5% in the first quarter of 2023 to $950.3 million.
Citi analysts have placed a buy rating on the Resmed share price with a $37 price target, the Australian reported. This implies an upside of 13% on the current share price.
Resmed shares are up 0.43% at the time of writing today and fetching $32.83. The ASX 200 has also lifted into the green today, up 0.25%.
The Resmed share price has fallen around 1% over the past 12 months.
Vicinity Centres
Vicinity invests and develops property, including shopping malls. In FY22, the ASX 200 share acquired a 50% interest in the Harbour Town premium outlets on the Gold Coast. Vicinity’s profit lifted by $1.2 billion in FY22 compared to FY21.
Analysts at Morgan Stanley have raised Vicinity to equal weight with a $2.26 price target, according to the publication. Vicinity shares are rising 0.74% today to $2.055. Morgan Stanley’s price target on Vicinity implies an upside of 10% on the current share price.
The Vicinity share price has soared almost 21% in a year.
Scentre Group
Scentre owns premium shopping malls in Australia and New Zealand. The company’s sales growth lifted by $3.5 billion in the 9 months to September 2022, compared to the corresponding time frame in 2021.
Scentre Group shares are 0.66% higher today and currently trading at $3.03. Morgan Stanley has lifted its rating on Scentre share price to overweight with a $3.55 price target. This implies an upside of 17% on today’s share price.
Scentre shares have slipped 0.5% in the last year.
The post 3 ASX 200 shares tipped to rise higher: experts appeared first on The Motley Fool Australia.
FREE Investing Guide for Beginners
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of January 5 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- 2 ASX 200 shares with multi-decade growth runways: Scott Phillips
- How to prepare your portfolio for the ‘old normal’: Scott Phillips
- Buy QBE and this ASX 200 blue chip share: broker
- Here are the top 10 ASX 200 shares today
- Are healthy returns on the horizon for ASX 200 healthcare shares in 2023?
Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/W3RMqa2
Leave a Reply